In our study, RSL3 decreased expression levels of MYB and Bcl-2, and RSL3 not only inhibited MDS cell proliferation as a single drug but also had synergistic effects with DAC to treat MDS cells, indicating promising clinical applications of RSL3 in the future. This evidence concerns the gene BCL2 and myelodysplastic syndrome.